-Reuters
Sesen Bio’s Bladder Cancer Trial Wrecked By Misconduct: Stat News
Sesen Bio Inc (NASDAQ: SESN) said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum.
Related Posts
RBC Capital Maintains Outperform on Constellation Software, Raises Price Target to C$2300
RBC Capital analyst Paul Treiber maintains Constellation Software (TSX:CSU) with a Outperform and raises the price target from C$2100 to C$2300.
Equity Bancshares Q2 EPS $1.03 Beats $0.62 Estimate
Equity Bancshares (NASDAQ:EQBK) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.62 by 66.13 percent. This is a 836.36 percent increase over earnings of $0.11 per share from
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $20
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $25 to $20.